COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #104
Source   PDF   Share   Tweet
See all 182 studies
Late treatment study
Abd-Elsalam et al., American Journal of Tropical Medicine and Hygiene, 10.4269/ajtmh.20-0873 (Peer Reviewed)
Hydroxych loroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
Small RCT in Egypt with 97/97 HC Q/control patients, showing 58% more recovery @28days for HC Q (53.6% HC Q, 34% control), p=0.009 (0.06 in the paper refers to the 5 combined recovery/death/ICU values).
No significant difference in ventilation and mortality (<=6 examples in each case). Authors note the "sample size was not adequately powered for [the] survival endpoint".
Other studies have also shown treated patient cases resolved faster. Continuing analysis past 28 days would be useful. Group characteristics are given, with for example 36% vs. 26% smokers, but they do not identify which group is which. Group 1 and 2 have 97 patients but the total given is 175.
death, ↑20.0%, p=1.00
no recovery, ↓30.0%, p=0.009, risk of no recovery at day 28
Source   PDF   Share   Tweet
See all 182 studies
Please send us corrections, updates, or comments.